Millennium Management’s Myriad Genetics MYGN Stock Holding History

Millennium Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-75,400	Closed	-$1.84M	–	6342
2024 Q2	$1.84M	Buy	+75,400	New	+$1.65M	﹤0.01%	3598
2024 Q1	–	Sell	-30,000	Closed	-$574K	–	6481
2023 Q4	$574K	Buy	+30,000	New	+$519K	﹤0.01%	4559
2021 Q3	–	Sell	-10,000	Closed	-$306K	–	7083
2021 Q2	$306K	Sell	10,000 -10,000	-50%	-$289K	﹤0.01%	5706
2021 Q1	$609K	Buy	+20,000	New	+$568K	﹤0.01%	4664
2019 Q3	–	Sell	-111,600	Closed	-$3.1M	–	4421
2019 Q2	$3.1M	Sell	111,600 -98,400	-47%	-$2.78M	﹤0.01%	2129
2019 Q1	$6.97M	Buy	+210,000	New	+$6.39M	0.01%	1533
2017 Q4	–	Sell	-170,000	Closed	-$6.15M	–	3978
2017 Q3	$6.15M	Buy	+170,000	New	+$4.85M	0.01%	1548
2014 Q4	–	Sell	-50,000	Closed	-$1.93M	–	4158
2014 Q3	$1.93M	Buy	+50,000	New	+$1.87M	﹤0.01%	1889
2014 Q2	–	Sell	-38,400	Closed	-$1.31M	–	3707
2014 Q1	$1.31M	Sell	38,400 -261,600	-87%	-$8.1M	﹤0.01%	2064
2013 Q4	$6.29M	Buy	300,000 +245,300	+448%	+$6.2M	0.02%	991
2013 Q3	$1.28M	Buy	+54,700	New	+$1.55M	﹤0.01%	1948

Other funds holding MYGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management's MYGN Position: Q2 2026 in Review

Millennium Management reduced its Myriad Genetics (MYGN) stake by 0.73% in Q2 2026, selling an estimated $220K and leaving 6,620,372 shares worth $37.8M. The position accounts for 0.01% of the portfolio, ranked #1080.

Millennium Management first reported a position in MYGN in Q2 2013 and has held it in 47 quarters since. The position peaked at $142M in Q3 2024. 196 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

Millennium Management held 6,620,372 shares of Myriad Genetics worth $37.8M as of Q2 2026.
Millennium Management sold 48,445 Myriad Genetics shares in Q2 2026, an estimated $220K.
Myriad Genetics made up 0.01% of Millennium Management's portfolio in Q2 2026, its #1080 holding.
Millennium Management first reported a position in Myriad Genetics in Q2 2013 and has held it in 47 quarters since.
Millennium Management's Myriad Genetics position peaked at $142M in Q3 2024.
196 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.